According to a study conducted by Columbia University economist Frank R. Lichtenberg, pharmaceutical innovation is paying off for American consumers by improving the quality of their lives, and for payers by lowering total healthcare expenditures.
According to a study conducted by Columbia University economist Frank R. Lichtenberg, pharmaceutical innovation is paying off for American consumers by improving the quality of their lives, and for payers by lowering total healthcare expenditures.
The study concludes that savings in other medical spending significantly offsets spending on newer prescription drugs among American consumers. The conclusions are based on analysis of the 1996 Medical Expenditure Panel Survey, the most current nationally representative database on the use of healthcare services and spending.
In his study, "Are the Benefits of Newer Drugs Worth Their Cost? Evidence from the 1996 MEPS," Lichtenberg found that people who used newer prescription drugs were less likely to die or to lose time at work, and spent fewer days in the hospital.
As a result, consumers of newer prescription drugs tended to spend significantly less on other healthcare services, thereby reducing overall expenditures. According to Lichtenberg, the cost of newer drugs was offset by an estimated fourfold reduction in non-drug spending.
"The art of good medical care involves treating the whole patient. Likewise, we must take a broader look at healthcare spending to understand both the direct and indirect effects of how we spend our healthcare dollars in order to determine where we are experiencing the greatest benefits," said Karen Williams, president of the Washington-based National Pharmaceutical Council, which sponsored the study. "This new data by Dr. Lichtenberg shows the importance of understanding the overall value of pharmaceuticals, not only to individual patients, but to society as a whole." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.